Cannabinoids and sleep in autism (CSHQ): placebo-controlled trial

Introduction and clinical context

The study Cannabinoids and sleep in autism (CSHQ): placebo-controlled trial (PMC · 2022) is part of the scientific research on the use of cannabinoids in autism / asd.

In autism spectrum disorder (ASD), research with CBD-rich cannabis focuses on challenging behaviors, anxiety, socialization and sleep. There are randomized clinical trials and feasibility studies with signs of benefit in some children and adolescents, although primary outcomes have not always been met and the evidence is still developing. Pediatric use requires caution, prescription and specialized follow-up, with family involvement.

Understanding what science shows about the use of cannabinoids in autism / asd helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Placebo-controlled study (150 children/adolescents with ASD) assessing sleep parameters via the CSHQ scale. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In ASD, research links the endocannabinoid system to the regulation of social behavior, anxiety and sleep, with CBD-rich extracts seeking an anxiolytic and modulating effect without significant psychoactivity. Safety in children is a priority: effects such as drowsiness, appetite changes and irritability require monitoring, as do drug interactions. The dose should be low and titrated cautiously, under specialized follow-up and with family involvement. This is a developing field, and use does not replace established behavioral therapies.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2022). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help in autism?

Studies with CBD report benefit in some cases (anxiety, sleep, behavior); the evidence is still developing.

Is it safe in children?

Pediatric use requires caution, prescription and specialized follow-up.